Inhibrx Biosciences, Inc. (INBX)
(Delayed Data from NSDQ)
$13.02 USD
-0.59 (-4.34%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $13.09 +0.07 (0.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INBX 13.02 -0.59(-4.34%)
Will INBX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for INBX
Inhibrx Biosciences Shares Latest Corporate Presentation Update
Inhibrx Biosciences files to sell 2.45M shares of common stock for holders
Inhibrx files to sell 2.45M shares of common stock for holders
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Top 4 Health Care Stocks That Are Preparing To Pump This Month